Cosunter(SZ:300436) news flash·2025-06-15 08:18Core Viewpoint - Guangshentang's innovative drug GST-HG141 has received ethical review approval for a Phase III clinical trial targeting chronic hepatitis B patients with poor antiviral response [1] Company Summary - Guangshentang (300436.SZ) announced that its subsidiary Guangshen Zhonglin has obtained ethical review approval from the ethics committee of the Tree Lan (Hangzhou) Hospital for the clinical trial of GST-HG141 [1] - GST-HG141 is a novel hepatitis B core protein/nucleocapsid regulator, representing a new mechanism in the development of antiviral drugs for hepatitis B [1] - The company holds global intellectual property rights for GST-HG141, which still requires completion of registration clinical research and approval from national drug review authorities before it can be marketed [1] Industry Summary - The approval of GST-HG141 for clinical trials indicates a potential advancement in the treatment options available for chronic hepatitis B, particularly for patients who do not respond well to existing antiviral therapies [1]